Smey Deploys AI Fermentation to Replace Volatile Cocoa and Palm Fats
French techbio firm Smey is developing non-GM, yeast-derived lipid alternatives to cocoa, avocado, and palm oils. While personal care applications scale first, European Novel Food authorisation remains the primary commercial bottleneck for nutritional brands.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Paris, France — 21 October 2026
French biotechnology startup Smey has revealed an artificial intelligence platform designed to ferment yeast-derived fats, offering food and nutraceutical manufacturers an alternative to volatile agricultural commodities. Headquartered in France with laboratory facilities at the IZB biotechnology centre in Martinsried, Germany, the company is developing precision-fermented alternatives to cocoa butter, avocado oil, and palm oil using its proprietary Lipid Atlas discovery engine.
Rather than modifying conventional agricultural oils through chemical interesterification or fractionation, Smey reverses formulation logic. Its machine learning models analyse lipid datasets to predict which natural yeast strains can express precise triglyceride profiles. Crucially, the process avoids genetic modification by screening wild-type organisms. Smey's initial ingredient portfolio—comprising Noyl Cocoa, Noyl Avocado, and Noyl Palm—targets commodity inputs exposed to severe agricultural disruption and price spikes. By calibrating fermentation parameters, the platform allows industrial processors to target bespoke solid fat content curves, oxidation resistance, and melting temperatures for specialized delivery systems.
Scaling industrial capacity and bringing unit costs down to parity with commodity fats represent the primary operational hurdles. Smey is mitigating scale-up capital risk by commercialising these lipids first within the higher-margin personal care sector, using those initial production runs to refine downstream processing and reduce per-kilogram fermentation expenditure. While manufacturing throughput will dictate minimum order quantities for food accounts, statutory European approvals determine the actual product launch window.
What this means for France
For French supplement manufacturers, contract packagers, and functional food formulators, Smey provides a strategic hedge against tropical supply chain instability. Formulators developing lipid excipients, softgel suspension matrices, and meal replacement bars face compressed margins from escalating cocoa costs and stricter European Union deforestation compliance directives impacting conventional palm oil. However, rapid commercial adoption is precluded by regulatory timelines: yeast-derived oils require formal Novel Food authorisation under European Commission Regulation (EU) 2015/2283 before commercial marketing across France. Technical teams should engage Smey during upcoming pilot sampling to benchmark lipid stability, emulsification, and melting behaviour, preparing reformulation dossiers well before commercial-scale volumes clear European regulatory scrutiny.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.